Philadelphia, Pennsylvania--(Newsfile Corp. - August 30, 2024) - Grabar Law Office is investigating whether officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties owed to the company.
If you have held GoodRx shares since on or shortly after the Company's September 23, 2020 IPO, and would like to learn more about the investigation, your rights, and potential for recovery, please visit https://grabarlaw.com/the-latest/GoodRx-Shareholder-Investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.
WHY: A recently filed federal securities fraud class action complaint alleges that GoodRx Holdings, Inc. (NASDAQ: GDRX), via certain of its officers and directors, made materially false and/or misleading statements, as well as failed to disclose that: (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescription transactions revenue (the Company's primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx's revenues for purchases at Kroger's pharmacies; and (3) as a result, representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis when made.
WHAT YOU CAN DO NOW: Current GoodRx shareholders who have held GoodRX shares since on or shortly after September 23, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/GoodRx-Shareholder-Investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221613
